February 13th 2025
Reviewing current and emerging trends in imaging utilization and the impact of attrition rates and radiology residency positions on the field, researchers explore the future of radiology with two new provocative studies.
Emerging PET/CT Agent May Enhance Diagnosis for Smaller Lesions of Clear Cell Renal Cell Carcinoma
September 20th 2023For cT1 renal masses < 4 cm and renal masses < 2 cm, the PET/CT agent 89Zr-DFO-girentuximab had respective sensitivity rates of approximately 85 percent and 96.7 percent for diagnosing clear cell renal cell carcinoma, according to research recently presented at the European Association of Nuclear Medicine (EANM) 2023 Congress.
CMS Approves NTAP Reimbursement for Molecular Imaging Agent Cytalux
August 10th 2023Through a new technology add-on payment (NTAP), the use of Cytalux will reportedly be reimbursed by CMS up to 65 percent of the cost of the molecular imaging agent, which is FDA-approved for intraoperative imaging of ovarian and lung cancer.
Emerging Perspectives on Amyloid PET Imaging for Alzheimer's Disease
July 21st 2023In a video interview, Jacob Dubroff, M.D., Ph.D., discussed the potential impact of the recent CMS proposal to rein in Medicare coverage restrictions on the use of amyloid positron emission tomography (PET) for patients with Alzheimer’s disease.
CMS Proposes Lift of Coverage Restrictions on PET Imaging for Alzheimer's Disease
July 19th 2023Recognizing the advent of beta amyloid-targeted therapies for the treatment of Alzheimer’s disease, the Centers for Medicare and Medicaid (CMS) has proposed eliminating coverage restrictions that limit amyloid positron emission tomography (PET) scans to clinical trial participants and one amyloid PET scan per lifetime.
The Rise of NPP Image Interpretation: What New Radiology Research Reveals
July 11th 2023In a retrospective review of over 110 million imaging claims for patients with commercial insurance or Medicare Advantage, researchers noted key trends signaling significant increases in imaging billed by non-physician practitioners (NPPs).
FDA Clears Image Processing Software with Emphasis on Nuclear Medicine Imaging Workflow
June 21st 2023The InterView Fusion and InterView XP reportedly improve image quality for single-photon emission computed tomography (SPECT) and offer imaging tools specifically geared to common nuclear medicine studies ranging from bone imaging to cardiac assessment and lung imaging.
Brain PET Study Suggests Link Between Early Amyloid Accumulation and Repetitive Subconcussive Trauma
May 9th 2023After five months of exposure to repeated blast events, the majority of nine otherwise healthy military instructors had significantly increased amyloid deposition in the brain, according to positron emission tomography (PET) findings from a new study.
Is PET/CT Better than CT for Monitoring Metastatic Breast Cancer Treatment?
April 10th 2023A recent prospective study found that progression-free survival (PFS) and disease-specific survival (DSS) were significantly associated with breast cancer tumor treatment response on 2-(18F)FDG-PET/CT imaging in comparison to contrast-enhanced computed tomography (CT), which showed no evidence of a significant association with tumor response.